2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…2021 American Transplant Congress
T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv+ Posttransplant Lymphoproliferative Disease (PTLD)
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…2020 American Transplant Congress
Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation
National Center for Child Health and Development, Tokyo, Japan
*Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…2020 American Transplant Congress
Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database
1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ
*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »